Darunavir: Anti-HIV agent HIV protease inhibitor

Drugs of the Future

Volumn 30, Issue 5, 2005, Pages 441-449

  Sorbera, L A ^a   Castaner J ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATORVASTATIN; BRECANAVIR; DARUNAVIR; KYNOSTATIN 272; LOPINAVIR; MACROGOL 400; NELFINAVIR; PL 100; PL 337; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; NONHUMAN; SIDE EFFECT;

EID: 22244485391     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.05.904227     Document Type: Article

References (34)

1. Erickson, J.W., Gulnik, S.V., Ghosh, A.K., Hussain, K.A. (US Department of Health & Human Services; University of Illinois). Multi-drug resistant retroviral protease inhibitors and associated methods. WO 9967254, WO 9967417, JP 2002518063.
2. Ghosh, A.K., Kincaid, J.F., Cho, W. et al. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg Med Chem Lett 1998, 8: 687-90.
3. Ghosh, A.K., Leshchenko, S., Noetzel, M. Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: Synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114). J Org Chem 2004, 69: 7822-9.
4. Ghosh, A.K., Leshchenko, S., Noetzel, M.W. (University of Illinois). Method of preparing (3R,3aS,6aR)-3-hydroxyhexahydrofuro[2,3,-b]furan and related compounds. WO 0433462, US 2004127727.
5. Liu, C., Ng, J.S., Behling, J.R., Yen, C.H., Campbell, A.L., Fuzail, K.S., Yonan, E.E., Mehrotra, D.V. Development of large-scale process for an HIV protease inhibitor. Org Process Res Dev 1997, 1:45-54.
6. Surleraux, D.L.N.G., Tahri, A., Verschueren, W.G. et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 2005, 48: 1813-22.
7. Prous Science Drug R&D Backgrounders: HIV and AIDS (online publication). Updated May 23, 2005.
8. Brettle, R.P., Wilson, A., Povey, S., Morris, S., Morgan, R., Leen, C.L., Hutchinson, S., Lewis, S., Gore, S. Combination therapy for HIV: The effect on inpatient activity, morbidity and mortality of a cohort of patients. Int J STD AIDS 1998, 9: 80-7.
9. Mocroft, A., Vella, S., Benfield, T.L. et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 352: 1725-30.
10. Piot, P., Bartos, M., Ghys, P.D., Walker, N., Schwartländer, B. The global impact of HIV/AIDS. Nature 2001, 410: 968-73.
11. Selik, P.M., Glynn, M.K., McKenna, MT. Diagnoses of HIV/AIDS - 32 States, 2000-2003 MMWR 2004, 53: 1106-10.
12. Bartlett, J.A., DeMasi, R., Quinn, J., Moxham, C., Rousseau, F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001, 15: 1369-77.
13. Gulick, R.M., Mellors, J.W., Havlir, D. et al. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000, 133(1): 35-9.
14. Koh, Y., Nakata, H., Maeda, K. et al. Novel bis- tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC 114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003, 47: 3123-9.
15. King, N.M., Prabu-Jeyabalan, M., Nalivaika, E.A., Wigerinck, P., de Béthune, M.-P., Schiffer, C.A. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004, 78: 12012-21.
16. Tie, Y., Boross, P.I., Wang, Y.-F., Gaddis, L., Hussain, A.K., Leshchenko, S., Ghosh, A.K., Louis, J.M., Harrison, R.W., Weber, I.T. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 2004, 338: 341-52.
17. De Meyer, S., Azijn, H., Van Ginderen, M., De Baere, I., Pauwels, R., de Béthune, M.-P. In vitro selection experiments demonstrate an increased genetic barrier to resistance development to TMC114 as compared with currently licensed protease inhibitors. Antivir Ther 2002, 7(2, Suppl. 1): Abst 5.
18. De Meyer, S., Van Marck, H., Veldeman, J., McKenna, P., Pauwels, R., de Béthune, M.-P. Antiviral activity of TMC114, a potent next-generation protease inhibitor, against > 4000 recent recombinant clinical isolates exhibiting a wide range of (protease inhibitor) resistance profiles. Antivir Ther 2003, 8(3): Abst 17.
19. De Meyer, S., Van Marck, H., Van Den Bulcke, T., Vingerhoets, J., Azijn, H., Pauwels, R., de Béthune, M.-P. Phenotypic and genotypic profiling of TMC114, a potent next-generation PI, against some 1600 recent PI-resistant clinical isolates. 11th Conf Retroviruses Opportunistic Infect (Feb 8-11, San Francisco) 2004, Abst 620.
20. Lo Cicero, M., Bulgheroni, E., Zampiero, A., Soster, F., Viganò, O., Galli, M., de Bethune, M.-P., De Meyer, S., Rusconi, S. TMC114: In vitro activity against HIV-1 primary isolates with reduced susceptibility to multiple protease inhibitors. 7th Int Congr Drug Ther HIV Infect (Nov 14-18, Glasgow) 2004, Abst P315.
21. van der Geest, van der Sandt, I., Gille, D., Groen, K., Tritsmans, L., Stoffels, P. Safety, tolerability and pharmacokinetics of escalating single oral doses of TMC114, a novel protease inhibitor (PI) highly active against HIV-1 variants resistant to other PIs. 41st Intersci Conf Antimicrob Agents Chemother (Dec 16-19, Chicago) 2001, Abst 1-1934.
22. Hoetelmans, R., Lefebvre, E., van der Sandt, I., Marien, K., De Pauw, M., Peeters, M., van der Geest, R., Vanstockem, M., Parys, W. Pharmacokinetics and effect of food on TMC114, a potent next generation protease inhibitor, boosted with low dose ritonavir. 5th Int Workshop Clin Pharmacol HIV Ther (April 1-3, Rome) 2004, Abst 39.
23. Hoetelmans, R., Van der Sandt, I., De Pauw, M., Struble, K., Peeters, M., Van der Geest, R. TMC114, a next generation HIV protease inhibitor: Pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers. 10th Conf Retroviruses Opportunistic Infect (Feb 10-14, Boston) 2003, Abst 549.
24. Hoetelman, R., Marien, K., De Pauw, M., Peeters, M., Godderis, F., Woodfall, B., Lefebvre, E. Pharmacokinetic interaction between TMC114/ritonavir (RTV) and tenofovir in healthy volunteers. 15th Int AIDS Conf (July 11-16, Bangkok) 2004, Abst TuPeB4634.
25. Hoetelman, R., Lasure, A., Koester, A., De Pauw, M., Van Baelen, B., Peeters, M., Parys, W., Lefebvre, E. The effect of TMC114, a potent next-generation HIV protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics. 44th Intersci Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington DC) 2004, Abst H-865.
26. Arasteh, K., Clumeck, N., Pozniak, A. et al. Antiretroviral activity, safety and pharmacokinetics of TMC114, a next-generation HIV-1 protease inhibitor (PI), in multiple PI-experienced patients. 2nd IAS Conf HIV Pathog Treat (July 13-16, Paris) 2003, Abst LB-16.
27. Arasteh, K., Clumeck, N., Pozniak, A. et al. First clinical results on antiretroviral activity, pharmacokinetics, and safety of TMC114, an HIV-1 protease inhibitor, in multiple PI-experienced patients. 10th Conf Retroviruses Opportunistic Infect (Feb 10-14, Boston) 2003, Abst 8.
28. De Meyer, S., Peeters, M., Jordens, C., McKenna, P., van der Geest, R., Pauwels, R., de Béthune, M.-P. TMC114, a potent next-generation protease inhibitor: Characterization of antiviral activity in multiple protease inhibitor-experienced patients participating in a phase IIa study. Antivir Ther 2003, 8(3): Abst 15.
29. Peeters, M., Van Baelen, B., De Meyer, S., de Bethune, M.-P., Muller, H., Hoetelmans, R., Lefebvre, E., Delaporte, E. TMC114/RTV activity in multiple PI-experienced patients: Correlation of baseline genotype, phenotype, pharmacokinetics, and IQ with antiviral activity at day 14. 11th Conf Retroviruses Opportunistic Infect (Feb 8-11, San Francisco) 2004, Abst 533.
30. Katlama, C., Berger, D., Bellos, N. et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. 12th Conf Retroviruses Opportunistic Infect (Feb 22-25, Boston) 2005, Abst 164LB.
31. TMC114. Tibotec Web Site January 24, 2005.
32. De Béthune, M.P., Xie, D., Azijn, H., Wigerinck, P., Hoetelmans, R., Pauwels, R. Influence of binding to human plasma proteins by protease inhibitors may be overestimated in current IQ models. 9th Conf Retroviruses Opportunistic Infect (Feb 24-28, Seattle) 2002, Abst 449-W.
33. King, N., Prabu-Jeyabalan, M., Wigerinck, P., de Béthune, M.-P., Schiffer, C.A. TMC114 binds within the substrate envelope of HIV-1 protease, which could account for its efficacy against multi-protease inhibitor-resistant virus. Antivir Ther 2003, 8(3): Abst 16.
34. De Bethune, M., Wigerinck, P., Jonckheere, H., Tahri, A., Maes, L., Pauwels, R., Erickson, J. TMC114, a highly potent protease inhibitor (PI) with an excellent profile against HIV variants highly resistant to current Pis. 41st Intersci Conf Antimicrob Agents Chemother (Dec 16-19, Chicago) 2001, Abst F-1677.